KR20050085091A - 심장 질환에서 에리스로포이에틴의 신규한 용도 - Google Patents
심장 질환에서 에리스로포이에틴의 신규한 용도 Download PDFInfo
- Publication number
- KR20050085091A KR20050085091A KR1020057009185A KR20057009185A KR20050085091A KR 20050085091 A KR20050085091 A KR 20050085091A KR 1020057009185 A KR1020057009185 A KR 1020057009185A KR 20057009185 A KR20057009185 A KR 20057009185A KR 20050085091 A KR20050085091 A KR 20050085091A
- Authority
- KR
- South Korea
- Prior art keywords
- erythropoietin
- erythropoietin protein
- protein
- kda
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (16)
- 심장 실환에서 철분 분포 장애를 치료하기 위한 약제의 제조에서 에리스로포이에틴 단백질의 용도.
- 제 1 항에 있어서,심장 질환이 심장 기능 부전인 용도.
- 제 1 항 또는 제 2 항에 있어서,에리스로포이에틴 단백질이 인간 에리스로포이에틴인 용도.
- 제 3 항에 있어서,에리스로포이에틴 단백질이 에포에틴 α 또는 에포에틴 β인 용도.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서,에리스로포이에틴 단백질이 내인성 유전자 활성화에 의해 발현되는 용도.
- 제 1 항 또는 제 2 항에 있어서,에리스로포이에틴 단백질이 서열 1 또는 서열 2의 아미노산 서열을 갖는 용도.
- 제 1 항 또는 제 2 항에 있어서,에리스로포이에틴 단백질이 1 내지 6개의 글라이코실화 자리의 첨가에 의해 변형되는 인간 에리스로포이에틴의 서열을 갖는 용도.
- 제 1 항 또는 제 2 항에 있어서,에리스로포이에틴 단백질이 다르베포에틴 α인 용도.
- 제 1 항 또는 제 2 항에 있어서,제 3 항 내지 제 8 항 중 어느 한 항에 정의된 에리스로포이에틴 단백질이 페길화되는 용도.
- 제 9 항에 있어서,에리스로포이에틴 단백질이 컨쥬게이트이고, 상기 컨쥬게이트는 하나 이상의 자유 아미노기를 가지며, 골수 세포가 망상 적혈구 및 적혈구의 생성을 증가시키는 생체 내 생물학적 활성을 갖고, 1 내지 6개의 글라이코실화 자리의 첨가 또는 하나 이상의 글라이코실화 자리의 재배열에 의해 변형되는 인간 에리스로포이에틴의 서열을 갖는 인간 에리스로포이에틴 및 그의 아날로그로 구성된 군으로부터 선택되는 에리스로포이에틴 단백질을 포함하고; 상기 에리스로포이에틴은 구조식 CO-(CH2)x-(OCH2CH2)m-OR의 n개의 폴리(에틸렌 글라이콜)기에 공유결합되는데, 각각의 폴리(에틸렌 글라이콜) 중의 -CO기는 상기 아미노기 중 하나와 아마이드 결합을 형성하며; 여기에서 R은 저급 알킬이고; x는 2 또는 3이고; m은 약 450 내지 약 900이고, n은 1 내지 3이고; 및 n 및 m은 에리스로포이에틴 단백질의 분자량을 뺀 컨쥬게이트의 분자량이 약 20kDa 내지 100kDa이 되도록 선택되는 용도.
- 제 10 항에 있어서,x가 2이고, m이 650 내지 750이고, n이 1이고, R이 메틸인 용도.
- 제 9 항에 있어서,에리스로포이에틴 단백질이 컨쥬게이트이고, 상기 컨쥬게이트는 하나 이상의 자유 아미노기를 가지며, 골수 세포가 망상 적혈구 및 적혈구의 생성을 증가시키는 생체 내의 생물학적 활성을 갖고, 1 내지 6개의 글라이코실화 자리의 첨가에 의해 변형된 인간 에리스로포이에틴 단백질의 일차 구조를 갖는 인간 에리스로포이에틴 단백질 및 그의 아날로그로 구성된 군으로부터 선택되는 에리스로포이에틴 단백질을 포함하고; 상기 에리스로포이에틴 단백질은 1 내지 3개의 저급 알콕시 폴리(에틸렌 글라이콜)기에 공유결합되고, 각각의 폴리(에틸렌 글라이콜)기는 화학식 -C(O)-X-S-Y-의 결합자를 통해 에리스로포이에틴 단백질과 공유결합으로 연결되는데, 결합자의 C(O)는 상기 아미노기 중의 하나와 아마이드 결합을 형성하며; X는 -(CH2)k- 또는 -CH2(O-CH2-CH2)k-이고, k는 1 내지 10이고, Y는이고; 각각의 폴리(에틸렌 글라이콜) 잔기의 평균 분자량은 약 20kDa 내지 약 40kDa이고, 컨쥬게이트의 분자량은 약 51kDa 내지 약 175kDa인 용도.
- 제 12 항에 있어서,하기 화학식의 에리스로포이에틴 컨쥬게이트를 갖는 용도:상기 식에서,n은 1 내지 3인 정수이고; m은 450 내지 900인 정수이고; R은 저급 알킬이고; X는 -(CH2)k- 또는 -CH2(O-CH2-CH2)k-이고, k는 1 내지 10이고, P는 X와 아마이드 결합을 형성하는 n개의 아미노기를 갖지 않는 에리스로포이에틴 단백질의 잔기이다.
- 유효량의 에리스로포이에틴 단백질을 투여하는 것을 포함하는 심장 질환에서 철분 분포 장애를 치료하기 위한 방법.
- 유효량의 에리스로포이에틴 단백질을 함유하는 것을 특징으로 하는 심장 질환에서 철분 분포 장애를 치료하기 위한 약제.
- 본원에서 상기에 정의된 발명.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02026342 | 2002-11-22 | ||
EP02026342.2 | 2002-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050085091A true KR20050085091A (ko) | 2005-08-29 |
KR100839302B1 KR100839302B1 (ko) | 2008-06-17 |
Family
ID=32337998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057009185A KR100839302B1 (ko) | 2002-11-22 | 2003-11-17 | 심장 질환에서 에리스로포이에틴의 신규한 용도 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7459436B2 (ko) |
EP (1) | EP1565206B1 (ko) |
JP (1) | JP2006512326A (ko) |
KR (1) | KR100839302B1 (ko) |
CN (1) | CN100531797C (ko) |
AR (1) | AR042097A1 (ko) |
AT (1) | ATE426411T1 (ko) |
AU (1) | AU2003288081B2 (ko) |
BR (1) | BRPI0316438C1 (ko) |
CA (1) | CA2505524C (ko) |
DE (1) | DE60326874D1 (ko) |
ES (1) | ES2321928T3 (ko) |
MX (1) | MXPA05005281A (ko) |
PL (1) | PL210256B1 (ko) |
RU (1) | RU2324494C2 (ko) |
WO (1) | WO2004047858A1 (ko) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
NZ617083A (en) * | 2003-08-27 | 2015-04-24 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
ES2460671T3 (es) | 2003-12-19 | 2014-05-14 | F. Hoffmann-La Roche Ag | Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
CA2593682C (en) | 2005-01-10 | 2016-03-22 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007026772A1 (ja) * | 2005-08-31 | 2007-03-08 | Kaneka Corporation | ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法 |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
CN101965200B (zh) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CN101870735B (zh) * | 2010-06-02 | 2013-06-12 | 北京精益泰翔技术发展有限公司 | 一种新型高糖基化促红细胞生成素免疫融合蛋白 |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
CN112661863A (zh) | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
SG10201912985RA (en) | 2013-07-12 | 2020-02-27 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP3988113A1 (en) | 2015-06-19 | 2022-04-27 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
WO2022063082A1 (zh) * | 2020-09-22 | 2022-03-31 | 美国杰科实验室有限公司 | 一种糖基化修饰的促红细胞生成素及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS57183508A (en) * | 1981-05-07 | 1982-11-11 | Nippon Piston Ring Co Ltd | Compound valve seat |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4745099A (en) | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
JP2858752B2 (ja) | 1987-04-10 | 1999-02-17 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
DK0452484T3 (da) | 1989-11-06 | 1996-10-14 | Cell Genesys Inc | Fremstilling af proteiner ved homolog rekombination |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
KR0176693B1 (ko) | 1989-12-22 | 1999-04-01 | 레지널드 디. 쇼트보그; 제롬 반 쥘렌 | 조절요소를 사용한 내인성 유전자의 발현을 변형시키는 방법 |
GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5324650A (en) | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
EP0977582B1 (de) | 1997-03-18 | 2002-08-14 | Roche Diagnostics GmbH | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
ATE291436T2 (de) | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
US20020065214A1 (en) | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
KR100645843B1 (ko) | 2000-12-20 | 2006-11-14 | 에프. 호프만-라 로슈 아게 | 에리트로포이에틴 접합체 |
EP1425589B1 (en) | 2001-09-14 | 2007-12-05 | F. Hoffmann-La Roche Ag | Differential diagnosis of disorders of iron metabolism |
-
2003
- 2003-11-12 US US10/706,701 patent/US7459436B2/en not_active Expired - Lifetime
- 2003-11-17 JP JP2004554368A patent/JP2006512326A/ja active Pending
- 2003-11-17 MX MXPA05005281A patent/MXPA05005281A/es active IP Right Grant
- 2003-11-17 ES ES03779949T patent/ES2321928T3/es not_active Expired - Lifetime
- 2003-11-17 CA CA2505524A patent/CA2505524C/en not_active Expired - Lifetime
- 2003-11-17 AT AT03779949T patent/ATE426411T1/de active
- 2003-11-17 PL PL377590A patent/PL210256B1/pl unknown
- 2003-11-17 RU RU2005119649/15A patent/RU2324494C2/ru active
- 2003-11-17 CN CNB2003801038773A patent/CN100531797C/zh not_active Expired - Lifetime
- 2003-11-17 BR BRPI0316438A patent/BRPI0316438C1/pt active IP Right Grant
- 2003-11-17 EP EP03779949A patent/EP1565206B1/en not_active Expired - Lifetime
- 2003-11-17 WO PCT/EP2003/012822 patent/WO2004047858A1/en active Application Filing
- 2003-11-17 KR KR1020057009185A patent/KR100839302B1/ko active IP Right Grant
- 2003-11-17 AU AU2003288081A patent/AU2003288081B2/en not_active Expired
- 2003-11-17 DE DE60326874T patent/DE60326874D1/de not_active Expired - Lifetime
- 2003-11-20 AR ARP030104288A patent/AR042097A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ATE426411T1 (de) | 2009-04-15 |
EP1565206B1 (en) | 2009-03-25 |
BRPI0316438C1 (pt) | 2021-05-25 |
US7459436B2 (en) | 2008-12-02 |
PL377590A1 (pl) | 2006-02-06 |
BRPI0316438B1 (pt) | 2016-08-02 |
CA2505524A1 (en) | 2004-06-10 |
BR0316438A (pt) | 2005-10-11 |
CN100531797C (zh) | 2009-08-26 |
KR100839302B1 (ko) | 2008-06-17 |
DE60326874D1 (de) | 2009-05-07 |
RU2005119649A (ru) | 2006-03-20 |
US20040209802A1 (en) | 2004-10-21 |
AR042097A1 (es) | 2005-06-08 |
EP1565206A1 (en) | 2005-08-24 |
CA2505524C (en) | 2017-02-07 |
BRPI0316438B8 (pt) | 2016-09-27 |
PL210256B1 (pl) | 2011-12-30 |
ES2321928T3 (es) | 2009-06-15 |
MXPA05005281A (es) | 2005-07-25 |
CN1713919A (zh) | 2005-12-28 |
JP2006512326A (ja) | 2006-04-13 |
RU2324494C2 (ru) | 2008-05-20 |
WO2004047858A1 (en) | 2004-06-10 |
AU2003288081B2 (en) | 2007-02-01 |
AU2003288081A1 (en) | 2004-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100839302B1 (ko) | 심장 질환에서 에리스로포이에틴의 신규한 용도 | |
EP1536823B1 (en) | Use of erythopoietin | |
KR100510624B1 (ko) | 폴리에틸렌글리콜과의 에리트로포이에틴 결합체 | |
EP1696947B1 (en) | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases | |
KR100758044B1 (ko) | 신규한 약학 조성물 | |
RU2232163C2 (ru) | Конъюгаты эритропоэтина и полиэтиленгликоля, фармацевтические композиции (варианты), способ профилактического и/или терапевтического лечения нарушений и способ получения коньюгата или композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130531 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140529 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180329 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 12 |